Axon Enterprise, Inc. (NASDAQ:AXON) CFO Sells $1,643,885.10 in Stock

Axon Enterprise, Inc. (NASDAQ:AXON) CFO Brittany Bagley sold 4,338 shares of the company’s stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $378.95, for a total value of $1,643,885.10. Following the transaction, the chief financial officer now directly owns 98,825 shares in the company, valued at $37,449,733.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Axon Enterprise Stock Down 1.3 %

AXON stock opened at $379.61 on Friday. The company has a market cap of $28.69 billion, a price-to-earnings ratio of 111.00, a PEG ratio of 10.30 and a beta of 0.94. The company has a current ratio of 2.88, a quick ratio of 2.52 and a debt-to-equity ratio of 0.35. Axon Enterprise, Inc. has a 12 month low of $189.12 and a 12 month high of $385.00. The firm has a 50-day moving average of $338.92 and a two-hundred day moving average of $314.65.

Axon Enterprise (NASDAQ:AXON) last posted its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported $1.20 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.18. Axon Enterprise had a net margin of 16.06% and a return on equity of 9.34%. The business had revenue of $504.00 million during the quarter, compared to analysts’ expectations of $478.35 million. During the same quarter in the prior year, the company posted $0.80 EPS. The business’s revenue for the quarter was up 34.5% on a year-over-year basis. As a group, analysts forecast that Axon Enterprise, Inc. will post 1.79 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Axon Enterprise

A number of hedge funds have recently made changes to their positions in AXON. Norges Bank purchased a new position in Axon Enterprise in the 4th quarter valued at approximately $195,406,000. Motley Fool Asset Management LLC raised its holdings in shares of Axon Enterprise by 238.7% in the 1st quarter. Motley Fool Asset Management LLC now owns 492,140 shares of the biotechnology company’s stock valued at $153,981,000 after purchasing an additional 346,838 shares in the last quarter. 1832 Asset Management L.P. acquired a new stake in shares of Axon Enterprise in the 1st quarter valued at $81,630,000. Vanguard Group Inc. raised its holdings in shares of Axon Enterprise by 2.7% in the 1st quarter. Vanguard Group Inc. now owns 8,143,306 shares of the biotechnology company’s stock valued at $2,547,878,000 after purchasing an additional 212,401 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its holdings in shares of Axon Enterprise by 110.0% in the 4th quarter. Goldman Sachs Group Inc. now owns 276,011 shares of the biotechnology company’s stock valued at $71,302,000 after purchasing an additional 144,568 shares in the last quarter. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on AXON shares. Jefferies Financial Group began coverage on shares of Axon Enterprise in a report on Wednesday, July 17th. They set a “buy” rating and a $385.00 price objective on the stock. Bank of America began coverage on shares of Axon Enterprise in a report on Wednesday, July 17th. They issued a “buy” rating and a $380.00 price target on the stock. Craig Hallum upped their price target on shares of Axon Enterprise from $370.00 to $376.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. Barclays upped their price target on shares of Axon Enterprise from $381.00 to $387.00 and gave the company an “overweight” rating in a report on Wednesday, August 7th. Finally, Northland Securities upped their price target on shares of Axon Enterprise from $330.00 to $365.00 and gave the company an “outperform” rating in a report on Thursday, August 8th. Two investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $365.38.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.